Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice
Open Access
- 15 May 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , e812-e822
Abstract
Background: Rift Valley fever virus (RVFV) is a zoonotic arbovirus endemic to Africa and the Arabian Peninsula that can cause disease in humans and livestock. There are currently no licensed vaccines for human use, but several candidates are at the clinical trial, stage including DDVax™, a preparation of live-attenuated RVFV lacking the nonstructural proteins NSs and NSm (ΔNSsΔNSm). Multiple preclinical studies have shown that ΔNSsΔNSm is safe and immunogenic. Methods: The longitudinal study described in this manuscript examined the additional features of duration, sex, and dose in immunogenicity and protection provided by ΔNSsΔNSm. Female and male 8-week-old C57BL/6 mice were vaccinated with either a low or high dose of ΔNSsΔNSm and humoral (via neutralization assay and enzyme-linked immunosorbent assay) and cellular immunity (enzyme-linked immunospot and flow cytometry) were assessed over a period of 6 months. A subset of animals was challenged with a lethal dose of wild-type RVFV 6 months postvaccination. Results: All vaccinated animals were protected against lethal RVF disease 6 months postvaccination independent of dose or sex. Humoral immunity in the form of RVFV-specific neutralizing and binding antibodies decreased over time but remained detectable at the end of the study. The RVFV-specific CD4+ T cells also decreased by 6 months postvaccination. In contrast, virus-specific polyfunctional CD8+ T cells persisted at comparable levels throughout the study. Conclusions: This work demonstrates that a single low-dose ΔNSsΔNSm vaccine elicits a durable humoral and cellular immune response that persists over months and protects C57BL/6 mice against lethal RVF disease.Keywords
Funding Information
- National Institutes of Health (T32 AI060525)
- National Institutes of Health (AI171200)
- National Institutes of Health (AI183792)
- National Institutes of Health (U19 AI18984)
- National Institute of Allergy and Infectious Diseases (AI180311)
- Operations of The University of Pittsburgh Regional Biocontainment Laboratory
- Center for Vaccine Research
- UPMC Children's Hospital of Pittsburgh
This publication has 38 references indexed in Scilit:
- A safer cell-based yellow fever live attenuated vaccine protects mice against YFV infectioniScience, 2024
- Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trialThe Lancet Infectious Diseases, 2024
- Long-term immunity following yellow fever vaccination: a systematic review and meta-analysisThe Lancet Global Health, 2024
- Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn GlycoproteiniScience, 2020
- Rift Valley fever in animals and humans: Current perspectivesAntiviral Research, 2018
- A chikungunya fever vaccine utilizing an insect-specific virus platformNature Medicine, 2016
- Men and mice: Relating their agesLife Sciences, 2016
- Live attenuated vaccines: Historical successes and current challengesVirology, 2015
- Polyfunctional T cell responses are a hallmark of HIV‐2 infectionEuropean Journal of Immunology, 2008
- The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infectionVirology, 2007